-DOCSTART- -X- O
Objective. -X- _ O
To -X- _ O
investigate -X- _ O
the -X- _ O
safety -X- _ B-Outcome
( -X- _ I-Outcome
risk -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
efficacy -X- _ I-Outcome
( -X- _ I-Outcome
benefit -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ O
Echinacea -X- _ B-Intervention
purpurea -X- _ I-Intervention
extract -X- _ I-Intervention
in -X- _ O
the -X- _ O
prevention -X- _ B-Outcome
of -X- _ O
common -X- _ B-Patient
cold -X- _ I-Patient
episodes -X- _ I-Patient
in -X- _ O
a -X- _ O
large -X- _ O
population -X- _ O
over -X- _ O
a -X- _ O
4-month -X- _ O
period. -X- _ O
Methods. -X- _ O
755 -X- _ B-Patient
healthy -X- _ I-Patient
subjects -X- _ I-Patient
were -X- _ O
allocated -X- _ O
to -X- _ O
receive -X- _ O
either -X- _ O
an -X- _ O
alcohol -X- _ B-Intervention
extract -X- _ I-Intervention
from -X- _ I-Intervention
freshly -X- _ I-Intervention
harvested -X- _ I-Intervention
E. -X- _ I-Intervention
purpurea -X- _ I-Intervention
( -X- _ I-Intervention
95 -X- _ I-Intervention
% -X- _ I-Intervention
herba -X- _ I-Intervention
and -X- _ I-Intervention
5 -X- _ I-Intervention
% -X- _ I-Intervention
root -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ O
placebo. -X- _ B-Comparison
Participants -X- _ O
were -X- _ O
required -X- _ O
to -X- _ O
record -X- _ O
adverse -X- _ O
events -X- _ O
and -X- _ O
to -X- _ O
rate -X- _ O
cold-related -X- _ O
issues -X- _ O
in -X- _ O
a -X- _ O
diary -X- _ O
throughout -X- _ O
the -X- _ O
investigation -X- _ O
period. -X- _ O
Nasal -X- _ O
secretions -X- _ O
were -X- _ O
sampled -X- _ O
at -X- _ O
acute -X- _ O
colds -X- _ O
and -X- _ O
screened -X- _ O
for -X- _ O
viruses. -X- _ O
Results. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
293 -X- _ B-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
occurred -X- _ I-Outcome
with -X- _ I-Outcome
Echinacea -X- _ I-Outcome
and -X- _ I-Outcome
306 -X- _ I-Outcome
with -X- _ I-Outcome
placebo -X- _ I-Outcome
treatment. -X- _ I-Outcome
Nine -X- _ I-Outcome
and -X- _ I-Outcome
10 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
participants -X- _ I-Outcome
experienced -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
were -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
possibly -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
study -X- _ I-Outcome
drug -X- _ I-Outcome
( -X- _ I-Outcome
adverse -X- _ I-Outcome
drug -X- _ I-Outcome
reactions -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Thus -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ I-Outcome
Echinacea -X- _ I-Outcome
was -X- _ I-Outcome
noninferior -X- _ I-Outcome
to -X- _ I-Outcome
placebo. -X- _ I-Outcome
Echinacea -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
total -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
cold -X- _ I-Outcome
episodes -X- _ I-Outcome
, -X- _ I-Outcome
cumulated -X- _ I-Outcome
episode -X- _ I-Outcome
days -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
group -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
pain-killer -X- _ I-Outcome
medicated -X- _ I-Outcome
episodes. -X- _ I-Outcome
Echinacea -X- _ I-Outcome
inhibited -X- _ I-Outcome
virally -X- _ I-Outcome
confirmed -X- _ I-Outcome
colds -X- _ I-Outcome
and -X- _ I-Outcome
especially -X- _ I-Outcome
prevented -X- _ I-Outcome
enveloped -X- _ I-Outcome
virus -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Echinacea -X- _ I-Outcome
showed -X- _ I-Outcome
maximal -X- _ I-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
recurrent -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
preventive -X- _ I-Outcome
effects -X- _ I-Outcome
increased -X- _ I-Outcome
with -X- _ I-Outcome
therapy -X- _ I-Outcome
compliance -X- _ I-Outcome
and -X- _ I-Outcome
adherence -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
protocol. -X- _ I-Outcome
Conclusions. -X- _ O
Compliant -X- _ O
prophylactic -X- _ O
intake -X- _ O
of -X- _ O
E. -X- _ B-Outcome
purpurea -X- _ I-Outcome
over -X- _ I-Outcome
a -X- _ I-Outcome
4-month -X- _ I-Outcome
period -X- _ I-Outcome
appeared -X- _ I-Outcome
to -X- _ I-Outcome
provide -X- _ I-Outcome
a -X- _ I-Outcome
positive -X- _ I-Outcome
risk -X- _ I-Outcome
to -X- _ I-Outcome
benefit -X- _ I-Outcome
ratio -X- _ I-Outcome
. -X- _ O

